HROW

HARROW, INC.

Healthcare Pharmaceutical Preparations Market cap: $1.0B All insider activity → Quote and statistics → Sign in to watch HROW Sign in to set a price alert

AI summary Insiders buy shares following first-quarter results and reaffirmed guidance

Insider Score Band 60–79

Research score: 63
AI adjustment: +9

Research score, not a recommendation.

Total bought$468.7K4 Form 4 purchases

Distinct insiders4open-market buyers

Lead insiderBAUM MARK LCEO

Cluster window2026-05-14 → 2026-05-18active

Market data

Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.

–

Why this score

Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.

Breadth number & diversity of participating insiders

63%

Seniority executive rank of buyers (CEO/CFO/Director)

97%

Commitment purchase size relative to company & holdings

72%

Context buying into stock weakness signals conviction

86%

Timing coordinated purchases within a tight window

99%

Routine-purchase discount × 1.00

Company-type / offering discount × 1.00

Net insider selling penalty − 15

Why are they buying?

AI · discretionary · catalyst credible · documented

Insiders purchased shares on the open market shortly after the release of Harrow's first-quarter 2026 financial results, where management reaffirmed full-year revenue guidance and expressed strong confidence in product demand and commercial momentum.

CEO Mark L. Baum and President Andrew R. Boll, alongside directors Lauren P. Silvernail and Adrienne L. Graves, acquired shares between May 14 and May 18, 2026, following a Q1 earnings release that highlighted record prescription performance for VEVYE and robust year-over-year demand for IHEEZO and TRIESENCE.

Filing references and sources

Harrow Announces First Quarter 2026 Financial Results (opens in a new tab)

Stock Price & Insider Purchase History

Daily close price with open-market insider purchases plotted over time

Loading price history…

Transactions

4 Form 4 trades · 4 insiders Sign in to download CSV

Purchases in this cluster, grouped by insider, largest first
Date	Insider	Role	Shares	Price	Value	Filing
2026-05-14	BAUM MARK L 5 purchases with a 63-day result · median +14.9%	CEO	10,000	$30.20	$302.0K	SEC filing for BAUM MARK L (opens in a new tab)
2026-05-14	BOLL ANDREW R. history of BOLL ANDREW R.'s purchases	President	3,500	$29.90	$104.7K	SEC filing for BOLL ANDREW R. (opens in a new tab)
2026-05-18	Graves Adrienne L history of Graves Adrienne L's purchases	Director	1,000	$31.07	$31.1K	SEC filing for Graves Adrienne L (opens in a new tab)
2026-05-18	SILVERNAIL LAUREN P history of SILVERNAIL LAUREN P's purchases	Director	1,000	$31.00	$31.0K	SEC filing for SILVERNAIL LAUREN P (opens in a new tab)
Total					$468.7K

Other buying runs at HROW

A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.

After this run became a cluster: 21 days +30.4%63 days +24.2%126 days –

Other insider buying runs at this company, newest first, with the return against the benchmark that followed
Window	Insiders	Total	Score	21 days	63 days	126 days	Status
2022-12-14 → 2022-12-22	5	$5.3M	68	-5.8%	+50.6%	+19.6%	closed
2016-12-19	3	$528.0K	55	–	–	–	closed